Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Pu X, Xiao Z, Li J, Wu Z, Ma Z, Weng J, Xiao M, Chen Y, Cao Y, Cao P, Wang Q, Xu Y, Li K, Chen B, Xu F, Liu L, Kong Y, Zhang H, Duan H, Wu L.
Pu X, et al. Among authors: xu f, xu y.
Lung Cancer. 2024 May;191:107538. doi: 10.1016/j.lungcan.2024.107538. Epub 2024 Mar 18.
Lung Cancer. 2024.
PMID: 38552544
Free article.
Clinical Trial.